22.39  -1.22 (-5.17%)		06-29 16:00
Open: 23.87 High: 23.87 Volume: 1,016,844		Pre. Close: 23.61 Low: 22.35 Market Cap: 1,087(M)

Short term
Mid term
Targets	6-month :	28.07	1-year :	32.79
Resists	First :	24.04	Second :	28.07
Pivot price	21.25
Supports	First :	21.43	Second :	19.81
MAs	MA(5) :	22.27	MA(20) :	21.09
	MA(100) :	31.69	MA(250) :	37.52
MACD	MACD :	-0.9	Signal :	-1.5
%K %D	K(14,3) :	76	D(3) :	78
RSI	RSI(14): 48.1
52-week	High :	48.25	Low :	19.15

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AORT ] has closed below upper band by 21.0%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	23.89 - 24.01	24.01 - 24.09
Low:	22.07 - 22.23	22.23 - 22.33
Close:	22.17 - 22.4	22.4 - 22.55

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Mon, 29 Jun 2026
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Benzinga

Mon, 29 Jun 2026
Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis - simplywall.st

Mon, 29 Jun 2026
Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections - grafa.com

Mon, 29 Jun 2026
Artivion stock rises after FDA approves AMDS device By Investing.com - Investing.com South Africa

Mon, 29 Jun 2026
Artivion, Inc.(NYSE: AORT) dropped from Russell 2000 Value Benchmark - marketscreener.com

Mon, 29 Jun 2026
Artivion (AORT) Secures FDA Approval for AMDS Hybrid Prosthesis - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	49 (M)
Shares Float	46 (M)
Held by Insiders	4.4 (%)
Held by Institutions	98.8 (%)
Shares Short	1,890 (K)
Shares Short P.Month	1,940 (K)

EPS	0.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	9.28
Profit Margin	2.5 %
Operating Margin	5.1 %
Return on Assets (ttm)	2.8 %
Return on Equity (ttm)	3.1 %
Qtrly Rev. Growth	17.5 %
Gross Profit (p.s.)	6.1
Sales Per Share	9.44
EBITDA (p.s.)	1.26
Qtrly Earnings Growth	0 %
Operating Cash Flow	58 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	89.55
PEG Ratio	643.7
Price to Book value	2.41
Price to Sales	2.36
Price to Cash Flow	18.74

Dividend	0.02
Forward Dividend	0
Dividend Yield	0.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.